A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer

被引:139
|
作者
Temel, Jennifer S. [1 ]
Greer, Joseph A. [1 ]
Goldberg, Sarah [1 ]
Vogel, Paula Downes [1 ]
Sullivan, Michael [1 ]
Pirl, William F. [1 ]
Lynch, Thomas J. [1 ]
Christiani, David C. [1 ]
Smith, Matthew R. [1 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
Non-small cell lung cancer; Exercise; Supportive care; QUALITY-OF-LIFE; HIGH-DOSE CHEMOTHERAPY; PHYSICAL-ACTIVITY; BREAST-CANCER; FUNCTIONAL ASSESSMENT; MEGESTROL-ACETATE; AEROBIC EXERCISE; OUTPATIENT REHABILITATION; PULMONARY REHABILITATION; RESISTANCE EXERCISE;
D O I
10.1097/JTO.0b013e31819d18e5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Exercise improves functional outcome and symptoms for certain cancer populations, but the feasibility, efficacy, and safety of structured exercise in patients with lung cancer is unknown. In this Study, we examined the feasibility of a hospital-based exercise program for patients with advanced non-small cell lung cancer. Methods: This study included patients with newly diagnosed advanced stage non-small cell lung cancer and Eastern Cooperative Oncology Group performance status 0-1. A physical therapist facilitated twice-weekly sessions of aerobic exercise and weight training over an 8-week period. The primary end point was feasibility of the intervention, defined as adherence to the exercise program. Secondary endpoints included functional capacity, measured by the 6-minute walk test and Muscle strength, as well as quality Of life, lung cancer symptoms and fatigue, measured by the Functional Assessment of Cancer Therapy-lung and Functional Assessment of Cancer Therapy-fatigue scales. Results: Between October 2004 and August 2007, 25 patients enrolled in the study. All participants received anticancer therapy during the Study period. Twenty patients (80%) underwent the baseline physical therapy evaluation. Eleven patients (44%) completed all 16 sessions. An additional 6 patients attended at least 6 sessions (range, 6-15), and 2 patients only attended one session. Study completers experienced a significant reduction in lung cancer symptoms and no deterioration in their 6-minute walk test or muscle strength. Conclusions: Although the majority of participants attempted the exercise program, less than half were able to complete the intervention. Those who completed the program experienced an improvement in their lung cancer symptoms. Community-based or briefer exercise interventions may be more feasible in this population.
引用
收藏
页码:595 / 601
页数:7
相关论文
共 50 条
  • [31] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [32] Chemotherapy for advanced non-small cell lung cancer
    Dubey, S
    Schiller, JH
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (01) : 101 - +
  • [33] Cetuximab in advanced non-small cell lung cancer
    Govindan, R
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4241S - 4244S
  • [34] Pemetrexed in advanced non-small cell lung cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Zeppa, Rosario
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (02) : 311 - 317
  • [35] Docetaxel in advanced non-small cell lung cancer
    Wakelee, H
    Ramalingam, S
    Belani, CP
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 13 - 24
  • [36] Treatment of advanced non-small cell lung cancer
    De Petris, L
    Crinò, L
    Scagliotti, GV
    Gridelli, C
    Galetta, D
    Metro, G
    Novello, S
    Maione, P
    Colucci, G
    de Marinis, F
    ANNALS OF ONCOLOGY, 2006, 17 : 36 - 41
  • [37] Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Joy
    Reckamp, Karen L.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 400 - 408
  • [38] Chemotherapy for advanced non-small cell lung cancer
    Thatcher, N
    LUNG CANCER, 2001, 34 : S171 - S175
  • [39] Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
    Kato M.
    Shukuya T.
    Takahashi F.
    Mori K.
    Suina K.
    Asao T.
    Kanemaru R.
    Honma Y.
    Muraki K.
    Sugano K.
    Shibayama R.
    Koyama R.
    Shimada N.
    Takahashi K.
    BMC Cancer, 14 (1)
  • [40] Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
    Madoka Kimura
    Tateaki Naito
    Hirotsugu Kenmotsu
    Tetsuhiko Taira
    Kazushige Wakuda
    Takuya Oyakawa
    Yasushi Hisamatsu
    Takaaki Tokito
    Hisao Imai
    Hiroaki Akamatsu
    Akira Ono
    Kyoichi Kaira
    Haruyasu Murakami
    Masahiro Endo
    Keita Mori
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    Supportive Care in Cancer, 2015, 23 : 1699 - 1708